Immutep’s FY2026 filing puts the full cost of the failed TACTI-004 Phase III trial on display: a larger loss, an impaired efti asset and a manufacturing investigation that remains unresolved. The company has A$68.9 million in cash and term deposits, which it forecasts will fund operations into the first half of calendar 2028 under current plans.
- A$79.3 million FY2026 net loss, up from A$61.4 million
- TACTI-004 discontinued after interim futility analysis
- A$3.1 million impairment charge against efti intellectual property
- Structural differences identified between 200L and 2,000L efti batches
- Cash resources forecast to last into the first half of 2028
TACTI-004 failure reshapes Immutep’s pipeline
Immutep Limited (ASX:IMM; Nasdaq:IMMP) is no longer treating its pivotal lung-cancer program as the centrepiece of the business. The company’s FY2026 Form 20-F confirms that TACTI-004, a global Phase III trial of eftilagimod alfa, or efti, in first-line non-small cell lung cancer, was stopped after a planned interim futility analysis found patients receiving efti with pembrolizumab and chemotherapy were underperforming the control arm.
The result was particularly damaging because the trial had been designed as a registrational study of roughly 756 patients and had enrolled 378 by February 2026. Immutep accepted the independent monitoring committee’s recommendation, halted recruitment and began winding down the study. Its root cause analysis remains incomplete. The filing says the review has identified subtle structural differences between efti manufactured at 2,000-litre scale for TACTI-004 and the 200-litre product used in earlier studies, but it does not establish that manufacturing caused the failed outcome.
The company’s TACTI-004 trial halt was followed by a review that, according to the filing, had not identified a clinical or trial-execution explanation by September 2026. Immutep has contracted a new 200-litre manufacturing run, while further work is needed to determine whether that product is comparable to the efti used in earlier studies and suitable for renewed clinical development.
Losses rise as development spending peaks
Immutep reported a net loss of A$79.3 million for FY2026, compared with A$61.4 million a year earlier. Research and development and intellectual property costs jumped to A$91.95 million from A$61.41 million, driven by clinical trial activity, efti manufacturing costs, TACTI-004 close-out work and the root cause analysis. The company also booked a A$3.1 million non-cash impairment charge against acquired efti intellectual property.
Revenue offers little comfort because it was dominated by a licensing transaction rather than product sales. Immutep recognised A$14.6 million in licensing revenue from its Dr. Reddy’s Laboratories agreement after receiving a US$20 million upfront payment in January 2026. It repaid US$10 million of that upfront payment in June after TACTI-004 was discontinued, while the agreement’s potential milestone pool of up to US$349.5 million and future royalties remain contingent on development and commercial progress.
Cash supports a reset, not commercial certainty
Cash and short-term investments totalled A$68.9 million at June 30, 2026, comprising A$63.7 million of cash and A$5.2 million in term deposits. Operating cash outflow was A$55.5 million for the year. Following targeted headcount reductions and lower operating spending, management forecasts that current resources will support operations into the first half of calendar 2028, although that estimate depends on future trial choices, spending and funding or partnering activity.
The reset leaves efti focused on narrower opportunities, including PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma. The filing records constructive FDA feedback on further development in the head and neck cancer population and orphan-drug designation for soft tissue sarcoma. Those signals are supportive, but they do not replace the evidence that would have come from the discontinued Phase III lung-cancer program.
IMP761 becomes the clearest independent program
Immutep is also advancing IMP761, its LAG-3 agonist antibody for autoimmune disease. The Phase I study continued into multiple ascending dosing during the final quarter of FY2026, with the company reporting statistically significant pharmacodynamic activity, a favourable pharmacokinetic profile and no serious treatment-related adverse events through doses of up to 14 mg/kg. These are early-stage findings in healthy volunteers, not evidence of efficacy in patients with autoimmune disease.
Investors are therefore left with two linked tests. First, can Immutep show that a new 200-litre efti batch is comparable to earlier material and secure a credible regulatory path? Second, can it fund the next set of studies without consuming the cash buffer before the development plan becomes clearer? Until those answers arrive, the company’s most valuable asset remains a hypothesis under investigation rather than a late-stage commercial proposition.
Bottom Line?
The next decisive catalyst is not another headline efficacy readout but the completion of the manufacturing analysis and proof that a comparable efti batch can support a credible, fundable trial strategy.
Questions in the middle?
- Will the root cause analysis establish whether the 2,000-litre manufacturing process contributed to TACTI-004’s failure?
- Can the new 200-litre efti batch demonstrate comparability and obtain regulatory clearance for future studies?
- Will the revised efti program and IMP761 progress within the forecast cash runway, or will additional capital be required sooner?